Bioharvest Sciences (BHST) | Financial Analysis & Statements
Bioharvest Sciences Inc. Micro-cap Consumer Defensive
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
9.1M
Gross Profit
5.2M
57.63%
Operating Income
-1.1M
-12.36%
Net Income
-2.2M
-24.31%
Balance Sheet Metrics
Total Assets
47.7M
Total Liabilities
22.2M
Shareholders Equity
25.4M
Debt to Equity
0.87
Cash Flow Metrics
Operating Cash Flow
-1.3M
Free Cash Flow
-2.9M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Bioharvest Sciences Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 34.5M | 25.2M | 12.7M | 5.5M | 2.1M |
| Cost of Goods Sold | 14.0M | 11.2M | 7.0M | 4.3M | 1.4M |
| Gross Profit | 20.5M | 13.9M | 5.6M | 1.2M | 670.0K |
| Gross Margin % | 59.3% | 55.4% | 44.5% | 22.2% | 31.9% |
| Operating Expenses | |||||
| Research & Development | 5.3M | 4.8M | 3.4M | 2.3M | 4.1M |
| Selling, General & Administrative | 19.1M | 15.7M | 12.1M | 9.4M | 4.8M |
| Other Operating Expenses | 1.2M | - | - | - | - |
| Total Operating Expenses | 25.6M | 20.5M | 15.4M | 11.7M | 8.9M |
| Operating Income | -5.6M | -7.0M | -10.0M | -10.6M | -8.5M |
| Operating Margin % | -16.2% | -27.7% | -78.6% | -193.0% | -403.9% |
| Non-Operating Items | |||||
| Interest Income | 54.0K | - | - | - | 0 |
| Interest Expense | 2.7M | 4.7M | 2.0M | 1.4M | 805.0K |
| Other Non-Operating Income | -1.8M | -483.0K | -501.0K | 861.0K | -484.0K |
| Pre-tax Income | -11.1M | -12.9M | -12.6M | -11.2M | -9.8M |
| Income Tax | 76.0K | 8.0K | - | - | - |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -11.1M | -12.9M | -12.6M | -11.2M | -9.8M |
| Net Margin % | -32.3% | -51.3% | -99.1% | -204.4% | -467.5% |
| Key Metrics | |||||
| EBITDA | -4.9M | -6.4M | -9.3M | -10.0M | -8.1M |
| EPS (Basic) | $-0.60 | $-0.80 | $-1.05 | $-0.70 | $-0.70 |
| EPS (Diluted) | $-0.60 | $-0.80 | $-1.05 | $-0.70 | $-0.70 |
| Basic Shares Outstanding | 18411153 | 16193787 | 13533160 | 13053644 | 12447697 |
| Diluted Shares Outstanding | 18411153 | 16193787 | 13533160 | 13053644 | 12447697 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Bioharvest Sciences Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 23.0M | 2.4M | 5.4M | 1.7M | 4.1M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 2.0M | 1.1M | 808.0K | 545.0K | 386.0K |
| Inventory | 4.6M | 3.7M | 2.5M | 1.4M | 928.0K |
| Other Current Assets | - | - | - | - | - |
| Total Current Assets | 30.5M | 7.9M | 9.1M | 4.3M | 5.7M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 830.0K | 890.0K | 4.2M | 3.9M | 3.9M |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 433.0K | 371.0K | 179.0K | 163.0K | 179.0K |
| Total Non-Current Assets | 17.2M | 17.1M | 6.0M | 5.1M | 4.5M |
| Total Assets | 47.7M | 25.0M | 15.0M | 9.4M | 10.2M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 2.6M | 3.5M | 1.8M | 1.1M | 875.0K |
| Short-term Debt | 1.6M | 4.7M | 20.9M | 8.9M | 386.0K |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 452.0K | 1.1M | 526.0K | - | 636.0K |
| Total Current Liabilities | 7.7M | 14.3M | 26.5M | 11.5M | 2.9M |
| Non-Current Liabilities | |||||
| Long-term Debt | 12.6M | 9.1M | 1.4M | 1.7M | 2.3M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 2.0M | 272.0K | 2.0M | 2.0M | - |
| Total Non-Current Liabilities | 14.5M | 9.4M | 3.4M | 3.8M | 4.4M |
| Total Liabilities | 22.2M | 23.7M | 29.9M | 15.3M | 7.4M |
| Equity | |||||
| Common Stock | 133.0M | 97.7M | 68.7M | 65.0M | 62.6M |
| Retained Earnings | -107.6M | -96.4M | -83.5M | -70.9M | -59.7M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 25.4M | 1.3M | -14.9M | -5.9M | 2.9M |
| Key Metrics | |||||
| Total Debt | 14.1M | 13.8M | 22.3M | 10.6M | 2.7M |
| Working Capital | 22.8M | -6.4M | -17.4M | -7.2M | 2.7M |
Balance Sheet Composition
Bioharvest Sciences Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -11.1M | -12.9M | -12.6M | -11.2M | -9.8M |
| Depreciation & Amortization | 1.6M | 1.3M | 840.0K | 712.0K | 389.0K |
| Stock-Based Compensation | 597.0K | 601.0K | 563.0K | 1.4M | 3.4M |
| Working Capital Changes | -2.4M | -1.6M | -1.1M | -1.0M | -1.1M |
| Operating Cash Flow | -7.7M | -11.6M | -11.4M | -10.1M | -8.4M |
| Investing Activities | |||||
| Capital Expenditures | -2.4M | -2.8M | -1.5M | -1.3M | -1.6M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -2.4M | -3.0M | -1.5M | -1.3M | -1.6M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 12.4M | 3.3M | 13.5M | 7.7M | 0 |
| Debt Repayment | -7.2M | -1.3M | -364.0K | -359.0K | -332.0K |
| Financing Cash Flow | 23.4M | 9.7M | 13.2M | 7.3M | 7.1M |
| Free Cash Flow | -9.6M | -9.5M | -10.0M | -10.5M | -8.4M |
| Net Change in Cash | 13.3M | -5.0M | 274.0K | -4.1M | -2.9M |
Cash Flow Trend
Bioharvest Sciences Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-7.30
Forward P/E
-51.53
Price to Book
3.90
Price to Sales
2.88
PEG Ratio
-51.53
Profitability Ratios
Profit Margin
-32.27%
Operating Margin
-12.37%
Return on Equity
-83.17%
Return on Assets
-9.59%
Financial Health
Current Ratio
3.97
Debt to Equity
55.42
Beta
1.40
Per Share Data
EPS (TTM)
$-0.60
Book Value per Share
$1.12
Revenue per Share
$1.87
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| BHST | 99.3M | -7.30 | 3.90 | -83.17% | -32.27% | 55.42 |
| Kellanova | 29.0B | 22.80 | 6.91 | 32.11% | 10.08% | 145.10 |
| Kraft Heinz | 26.0B | 13.01 | 0.62 | -12.84% | -23.44% | 52.10 |
| BRC | 129.3M | -8.38 | 2.72 | -54.86% | -2.99% | 91.21 |
| FitLife Brands | 90.2M | 14.12 | 2.01 | 15.86% | 7.77% | 103.75 |
| DDC Enterprise | 80.6M | 0.38 | 0.62 | -106.65% | -123.34% | 42.72 |
Financial data is updated regularly. All figures are in the company's reporting currency.




